How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Patent foramen ovale (PFO) closure in patients with cryptogenic ischaemic stroke

in the PFO closure procedure, followed by aspirin plus clopidogrel for one month, and aspirin only thereafter (doses not specified). Individuals in the medical therapy arm received 75mg clopidogrel daily as per NHS guidelines. In the model, patients could transition between four health states – stable, minor recurrent ischaemic stroke, moderate recurrent ischaemic stroke and dead – every 3 months over a 20-year time horizon. Thirty percent of the recurrent ischaemic strokes in the base case were assumed

2020 SHTG Advice Statements

2. Comparison of the Effect of Age (< 75 Versus >/= 75) on the Efficacy and Safety of Dual Therapy (Dabigatran+Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin+Aspirin+Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneo Full Text available with Trip Pro

Comparison of the Effect of Age (< 75 Versus >/= 75) on the Efficacy and Safety of Dual Therapy (Dabigatran+Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin+Aspirin+Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneo Comparison of the Effect of Age ( - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History (...) Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 10 Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden. PMID: 31924322 DOI: Item in Clipboard Full-text links Cite Abstract The RE-DUAL PCI trial reported that dabigatran dual therapy (110/150 mg twice daily, plus clopidogrel or ticagrelor) reduced bleeding events versus warfarin triple therapy (warfarin plus aspirin and clopidogrel or ticagrelor) in patients with atrial

2020 EvidenceUpdates

4. Heart Failure - Systolic Dysfunction

therapy, clopidogrel therapy (75mg/day) may be considered. Limited data suggest similar benefits in heart failure patients regarding mortality, hospitalizations, and bleeding episodes as compared to aspirin. Antithrombotics. Heart failure patients with non-valvular atrial fibrillation may be considered for alternative therapies other than warfarin. Newer agents e.g. dabigatran (a direct thrombin inhibitor) and rivaroxaban and apixaban (direct factor Xa inhibitors) appear to be more efficacious

2020 University of Michigan Health System

5. Clopidogrel / Acetylsalicylic acid Mylan

Clopidogrel / Acetylsalicylic acid Mylan Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to Send us a question Go to Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/628773/2019 EMEA/H/C/004996 Clopidogrel/Acetylsalicylic acid Mylan (clopidogrel (...) / acetylsalicylic acid) An overview of Clopidogrel/Acetylsalicylic acid Mylan and why it is authorised in the EU What is Clopidogrel/Acetylsalicylic acid Mylan and what is it used for? Clopidogrel/Acetylsalicylic acid Mylan is a medicine used to prevent problems caused by blood clots and hardening of the arteries, such as a heart attack, in adults who are already taking both clopidogrel and acetylsalicylic acid as separate tablets. It can be used in the following groups of patients who have a condition known

2020 European Medicines Agency - EPARs

6. Umbrella review and meta-analysis of antiplatelet therapy for peripheral artery disease

evidencia para recomendar la prescripción de antiagregantes plaquetarios después de una intervención endovascular periférica, situación que debería abordarse en ensayos aleatorizados con una potencia estadística adecuada. © 2019 BJS Society Ltd Published by John Wiley & Sons Ltd. Similar articles WS Jones et al. May 2013. PMID 23844447. - Review From a limited number of studies, it appears that aspirin has no benefit over placebo in the asymptomatic PAD patient; clopidogrel monotherapy is more

2020 EvidenceUpdates

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>